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Abstract
Inflammation plays an important role in the pathogenesis of intervertebral disc (IVD)
degeneration. The proinflammatory cytokine tumor necrosis factor alpha (TNF-α) has
shown markedly higher expression in degenerated human disc tissue compared with
healthy controls. Anti-inflammatory treatment targeting TNF-α has shown to allevi-
ate discogenic pain in patients with low back pain. Therefore, in vitro and ex vivo
inflammatory models utilizing TNF-α provide relevant experimental conditions for
drug development in disc degeneration research.
The current method article addressed several specific questions related to the model
establishment.
(a) The effects of bovine and human recombinant TNF-α on bovine nucleus pulposus
(NP) cells were compared. (b) The required dose for an inflammatory IVD organ cul-
ture model with intradiscal TNF-α injection was studied. (c) The effect of TNF-α
blocking at different stages of inflammation was evaluated.
Outcomes revealed that bovine and human recombinant TNF-α induced equivalent
inflammatory effects in bovine NP cells. A bovine whole IVD inflammatory model was
established by intradiscal injection of 100 ng TNF-α/ cm3 disc volume, as indicated by
increased nitric oxide, glycosaminoglycan, interleukin 6 (IL-6), and interleukin 8 (IL-8)
release in culture media, and upregulation of MMP3, ADAMTS4, IL-8, IL-6, and cyclo-
oxygenase (COX)-2 expression in NP tissue. However, results in human NP cells
showed that the time point of anti-inflammatory treatment was crucial to achieve sig-
nificant effects. Furthermore, anticatabolic therapy in conjunction with TNF-α inhibi-
tion would be required to slow down the pathologic cascade of disc degeneration.
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1 | INTRODUCTION
Low back pain (LBP) is the leading cause of disability worldwide.1 One
major cause for chronic LBP is symptomatic intervertebral disc
degeneration (IVDD).2-4 IVDD is characterized by extracellular matrix
(ECM) degradation, accelerated cartilaginous, and bone remodeling,
release of proinflammatory cytokines, altered spine biomechanics, angio-
genesis and neoinnervation, altogether potentially leading to chronic
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LBP, and disability.5-9 IVDD can be induced by mechanical stress, trauma,
infection, genetic predisposition, and inflammation.10-16
Inflammation plays a major role in disc degeneration, as
proinflammatory cytokines (ie, tumor necrosis factor alpha [TNF-α],
interleukin 1 beta [IL-1β], interleukin 6 [IL-6], interleukin 8 [IL-8],
interleukin 17 [IL-17], and interferon gamma [IFN-γ]) induce and trig-
ger discal ECM breakdown and accelerated catabolism by stimulation
of catabolic enzymes such as matrix metalloproteinases (MMPs) and a
disintegrin and metalloproteinase with thrombospondin motifs
(ADAMTS).6,17-20 Proinflammatory cytokines have shown elevated
expression in degenerative and symptomatic compared to healthy and
asymptomatic IVDs.16,21 Since therapeutic approaches for IVDD
remain limited, biological anti-inflammatory approaches to IVD regen-
eration have gained increasing interest. In cases of refractory LBP due
to IVDD, anti-inflammatory and/or anti-degenerative therapies such
as cytokine inhibition may relieve pain and slow down the progression
of the disease.22-31 Several studies indicated that cyclooxygenase-2
(COX2) inhibitors can reduce the inflammatory response in different
models.25-27 Soluble TNF receptor type II is able to significantly atten-
uate the effects of TNF-α on primary human IVD cells in vitro.28
Intradiscal administration of a TNF-α inhibitor, Etanercept, in LBP
patient can alleviate intractable discogenic LBP for up to 4 weeks.31
A degenerative disc exhibits increased TNF-α expression, not only
produced by immunocytes, but also by disc cells themselves.15,19,32
Furthermore, TNF-α can induce nucleus pulposus (NP) cells to pro-
duce other cytokines and chemokines that can further enhance the
inflammatory state by recruiting and activating immune cells.33 So far,
it is widely accepted that TNF-α contributes to disc degeneration by
decreasing the anabolism and increasing the catabolism of ECM.34
Additionally, exogenous TNF-α induces neuropathology and sensory
nerve growth into IVD, which indicated TNF-α might be the chemical
mediator of discogenic pain.35,36 Therefore, multiple in vitro, ex vivo,
and in vivo inflammatory IVD models have been established with
TNF-α.20,28,37-39 NP cells cultured with TNF-α in vitro showed
upregulated expression of catabolic enzymes, ADAMTS 4&5 and
MMP-1,-2,-3,-13, and inflammatory mediators, IL-1β, IL-6, IL-8, and
COX2, downregulated expression of ECM markers collagen II,
aggrecan, and versican.34,40-44 TNF-α has been shown to induce
MMP3 expression via nuclear factor κB (NF-κB) and mitogen-acti-
vated protein kinase pathways.45 Intradiscal injection of TNF-α in a
porcine model was sufficient to induce early-stage disc degeneration,
characterized by matrix loss, annular fissure formation, and vasculari-
zation.46 Lai et al reported that annular puncture with TNF-α injection
enhanced painful behavior with disc degeneration in a rat model.39
Ex vivo explant culture models bridge the gap between in vitro
and in vivo systems and reveal many advantages by maintaining the
native tissue environment and decreasing the consumption of experi-
mental animals. Compared with the small animals like mouse, rat and
rabbit, the IVDs from large animals such as sheep, dog and cow are
more similar to human. They show comparable size and loss of noto-
chordal cells in early adulthood as human IVD.47,48 Notochordal cells
have been reported to present anti-inflammation and regenerative
effect in IVDs.49,50 With those similarities, many bovine caudal IVD
organ culture models were established. van Dijk et al developed a NP tis-
sue explant culture model, and found that using polyethylene glycol to
raise culture medium osmolarity was able to maintain the NP tissue spe-
cific matrix composition.25,51 Whole bovine caudal IVD cultured under
either limited glucose condition or high-frequency loading condition led to
a significant drop in cell viability, while combined treatment with limited
glucose and high-frequency loading resulted in an additive increase in cell
death in both the NP and annulus fibrosus (AF), and an increase in
MMP13 gene expression.52 Purmessur et al cultured whole IVD organ
excluding the endplates with exogenous TNF-α in medium. Aggrecan deg-
radation products and β-galactosidase staining were enhanced by TNF-α
on day 21 without any recovery, when TNF-α was removed on day 7.38
Recently, our group has developed a proinflammatory and degenerative
IVD whole organ culture system to investigate the proinflammatory and
degenerative microenvironment operant in IVDD. Results indicated that a
combination of detrimental dynamic loading, nutrient deficiency and
intradiscal TNF-α injection could synergistically simulate the
proinflammatory and degenerative disease condition. However, intradiscal
TNF-α injection alone did not lead to a significant inflammatory effect.7
In the present study, we sought to establish TNF-α induced in
vitro and ex vivo IVD inflammation models, which would represent
preclinical testing systems for screening of anti-inflammatory drugs
for disc degeneration treatment. Specifically, the following questions
were addressed within this study:
1 Does TNF-α from bovine and human have the same
proinflammatory effect on bovine NP cells?
2 What is the optimal dose of TNF-α when utilized within an IVD inflam-
mation organ culture model induced by TNF-α intradiscal injection?
3 Does TNF-α inhibition at different stages of inflammation have
equal anti-inflammatory and/or regenerative effects on NP cells?
2 | MATERIALS AND METHODS
2.1 | Medium selection
Alpha Minimum Essential Medium (αMEM) has shown an advantage
compared with Dulbecco's Minimum Essential Medium (DMEM) in
terms of numbers and quality of cells acquired in mesenchymal stem
cells isolation and expansion.53 In the current study, human and
bovine NP cells isolation and expansion were performed with αMEM
according to previous publication.54 DMEM contains much higher
amount of vitamins, amino acids and glucose than αMEM. Therefore,
cells and IVD organ culture experiments with TNF-α and Etanercept
were performed with DMEM, due to a much higher cell density and
nutrition requirement in these experiments.
2.2 | NP cells isolation and expansion
Human NP cells were isolated from traumatic IVDs (2 donors, 34/
49 years old, male) with ethical approval (Cantonal Ethic Commission
2 of 12 DU ET AL.
Bern 2016). General consent was obtained from all patients before
surgery. All studies were performed in accordance with the ethical
standards as laid down in the 1964 Declaration of Helsinki and its
later amendments or comparable ethical standards. The IVDs were
classified as mildly degenerated by MRI (Pfirrmann grade 2-3). Bovine
NP cells were isolated from caudal intervertebral discs of 6 to 12-
month-old calves from local abattoirs immediately after death. NP cell
isolation was performed as described previously.55 The collected NP
tissue was cut into small pieces. Human NP tissue was incubated with
red blood cell lysis buffer (155 mM NH4Cl, 10 M KHCO3, and 0.1 mM
EDTA in Milli-Q water) to remove the red blood cells. The chopped
tissue was digested with 0.2% w/v Pronase (Roche, Mannheim, DE) in
αMEM (Gibco, Paisley, UK) for 1 hr, then digested with 65 U/mL colla-
genase type II (Worthington, Lakewood, NL) in αMEM / 10% fetal
bovine serum (FBS, PAN Biotech, Germany) in a spinner flask for 12
to 14 hours at 37C. The digested cell suspension was filtered through
a 100 μm cell strainer to obtain a single-cell suspension. NP cells were
expanded in αMEM supplemented with 10% FBS and 100 U/mL peni-
cillin and 100 mg/mL streptomycin (1% P/S, Gibco, Paisley, UK), incu-
bated at a hypoxic condition of 2% O2 at 37C. Culture medium was
changed twice a week. Passage 2 and 3 NP cells were used in the
current study.
2.3 | Effect of human and bovine recombinant
TNF-α on bovine NP cells
Bovine NP cells were seeded at a concentration of 60 000/cm2 in 12-
well plates with DMEM medium (containing 4.5 g/L glucose) sup-
plemented with 10% FBS. After cell attachment (24 hours after cell
seeding), the medium was exchanged to serum-free experimental
medium (DMEM supplemented with 1% ITS+, 1% nonessential amino
acid [NEAA, Gibco, Paisley, UK], 50 μg/mL ascorbate 2 phosphate and
1% P/S) with or without inflammatory inducers 10 ng/mL human
recombinant TNF-α (R&D systems, Zug, Switzerland) or 10 ng/mL
bovine recombinant TNF-α (R&D Systems, Zug, Switzerland). After
another 72 hours of culture, the cell monolayer was lysed and RNA
was isolated for gene expression analysis.
2.4 | Effect of human recombinant TNF-α and
TNF-α inhibition on human NP cells
Human NP cells were seeded into a six well-plate at a cell density of
30 000/cm2. One day after seeding, cells were treated with 10 ng/mL
(low dose) or 50 ng/mL (high dose) TNF-α in serum-free experimental
medium as described above for bovine NP cells TNF-α experiments.
The samples were collected at three timepoints, 6, 24, and 48 hours
after treatment, for gene expression analysis.
To investigate the effect of TNF-α blocking with the TNF-α inhib-
itor Etanercept (Enbrel, Pfizer, New York, New York), NP cells were
seeded as described above and cultured for 24 hours to allow for cell
attachment. Hereafter, cells were divided into 4 different groups:
(1) iNP—cells were treated with 10 ng/mL TNF-α for 48 hours, (2)
iNP-Eta—cells were treated with 10 ng/mL TNF-α and immediately
after 1 μg/mL Etanercept was added for 48 hours, (3) iNP-24 hours-
Eta—cells were treated with 10 ng/mL TNF-α, 24 hours after 1 μg/mL
Etanercept was added, and (4) iNP-24 hours-FM—cells were treated
with 10 ng/mL TNF-α, 24 hours after replaced to fresh medium with-
out TNF-α. Cells treated with serum-free culture medium as described
above served as negative control. All the cells were harvested for
gene expression analysis at 72 hours after seeding. The concentration
of Etanercept used here was selected according to previous studies,
showing that Etanercept at 0.01, 0.1 and 1 μg/mL induced less than
8% cell death in TNF-α transfected Jurkat cells, and in human NP cells
and AF cells cultured with Etanercept at 100, 250, 500, 1000, and
2000 μg/mL, cell proliferation was only suppressed with Etanercept at
500 μg/mL or higher.56,57 Therefore, the selected Etanercept concen-
tration at 1 μg/mL was assumed to have no cytotoxic effect on NP
cell culture in vitro.
2.5 | IVDs dissection
Bovine caudal IVDs were collected from fresh sacrificed 6 to 12-
month-old calves from local slaughterhouses. Disc dissection was per-
formed as described previously.58 Briefly, most of the muscle and soft
tissue were removed, whole IVDs with cartilage endplates (EPs) were
isolated with a band saw and redundant vertebral bone and growth
plate were carefully cut off to ensure two parallel planes of discs. Disc
height and diameter was then measured with a caliper. Disc vol-
ume = (long diameter + short diameter)/2)2 × π × disc height. The sur-
faces of EPs were cleaned using a Pulsavac Wound Debridement
Irrigation System (Zimmer, Minneapolis, USA) with Ringer's buffer to
remove the cutting debris and blood clots. After prewashing in PBS
with 10% P/S, IVDs were cultured in 6-well plates with 7.5 mL IVD
culture medium, DMEM supplemented with 1% P/S, 50 mg/mL
Primocin (Invitrogen, San Diego, California), 2% FBS, 50 μg/mL ascor-
bate 2 phosphate, 1% ITS+, 1% NEAA, at 37C, 5% CO2.
2.6 | IVD culture and intradiscal injection
IVDs having a diameter of 1.5 to 2.0 cm were selected for the current
study. IVDs were cultured free swelling during the night. Dynamic
loading was performed, at 0.02 to 0.2 MPa, 0.2 Hz for 2 hours per day
within a bioreactor.7 IVDs from each donor were randomly divided
into three groups: PBS, TNF-α and TNF-α + Etanercept. TNF-
α + Etanercept: 40 μL of TNF-α, containing 100 ng TNF-α/cm3 of disc
volume, was firstly injected into the disc, 30 minutes after 20 μL
Etanercept, containing 10 μg Etanercept per 100 ng TNF-α, was
injected into the disc. TNF-α: 40 μL of TNF-α, containing 100 ng TNF-
α/cm3 of disc volume, was injected into disc 30 minutes after 20 μL
PBS was injected. PBS: 40 and 20 μL PBS was injected into disc
sequentially. The injection was performed using a 30-gauge insulin
needle, after the first dynamic loading on day 1. The intradiscal
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injection dose of Etanercept was kept at the same ratio of TNFα to
Etanercept as in vitro, which is 1:100. IVDs were cultured with daily
dynamic loading and free swelling recovery overnight, the disc size of
IVDs was measured before and after loading.7 Culture media were
collected daily after free swelling for further analysis. The NP tissue
(gel-like inner core of 6-8 mm of diameter) was collected for gene
expression analysis on day 2 and day 5.
2.7 | Gene expression analysis
RNA samples were collected from monolayer NP cells by adding
0.5 mL TRI reagent (Molecular Research Centre Inc., Cincinnati, Ohio)
with 2.5 μL polyacryl carrier (Molecular Research Centre Inc) per well.
RNA isolation was performed according to the manufacturer's specifi-
cations. RNA isolation from NP tissues was performed as described
before.59 NP tissues, 150 to 200 mg per sample isolated from discs,
were cut into small pieces, snap-frozen in liquid nitrogen and pulver-
ized. The pulverized tissue was carefully collected and put into 3 mL
TRI reagent with 15 μL polyacryl carrier. The volume of the TRI
reagent was added according to the original NP tissue weight (3 mL
TRI for 150-200 mg tissue) with a volume ratio of >10:1 to supply
adequate TRI volume for RNA isolation. Samples were homogenized
immediately by a tissue-lyser. After centrifugation, the supernatant
was collected. Phase separation was performed by adding 100 μL
bromochloropropane per 1 mL of TRI reagent and centrifugation. The
aqueous phase was mixed with the same volume of 70% ethanol. The
following steps were performed using the QIAGEN RNeasy MINI kit
according to the manufacturer's protocol.
SuperScript VILO cDNA Synthesis Kit (Invitrogen) was used for
cDNA synthesis with 400 ng RNA per sample. The quantitative real-
time polymerase chain reaction (qRT-PCR) was conducted on
QuantStudio6 PCR System (Applied Biosystems). The primers and
probes used in qRT-PCR for human and bovine samples are shown in
Table 1. All the data were analyzed using 2−ΔΔCT method, with RPLP0
as an endogenous control. The RPLP0 showed similar Ct value with
different treatments, indicating TNFα and Etanercept did not show an
influence on the house keeping gene expression.
2.8 | Enzyme-linked immunosorbent assay
IL-6 and IL-8 content in bovine IVD organ culture media were
measured with enzyme-linked immunosorbent assay (ELISA) kits
(Kingfisher Biotech, St. Paul, Minnesota). Capture antibody:
anti-bovine IL-6 polyclonal antibody (KP0652B-100, Kingfisher
Biotech), anti-bovine IL-8 polyclonal antibody (PB1164B-100,
Kingfisher Biotech). Detection antibody: Biotinylated-anti-bovine
IL-6 (KPB0653B-050, Kingfisher Biotech), Biotinylated-anti-
bovine IL-8 (PBB1165B-050, Kingfisher Biotech). Experiments
were performed according to the manufacturer's protocol. The
results of the ELISA were presented as the original concentration
in the media without normalization.
2.9 | Glycosaminoglycan and nitric oxide
measurement
The amount of Glycosaminoglycans (GAGs) released in IVDs culture
media was measured by using the 1,9-dimethylmethylene blue dye
method.60 The level of GAG release from each IVD at each time point
after injection was normalized to the amount released on day 1 before
injection by dividing the corresponding day's GAG release content
with the amount of GAG release on day 1. The concentration of nitric
oxide (NO) in the culture media of IVDs was detected as the level of
its stable oxidation product, nitrite (NO2−), using the Griess Reagent
Kit (Promega, USA). The NO concentrations in the media are pres-
ented in the results section without normalization.
2.10 | Statistical analysis
Statistical analyses were performed using the GraphPad Prism 7
software (GraphPad Software, Inc., La Jolla, California). D'Agostino-
Pearson omnibus normality test was used to define whether the data
were normally distributed. For data that were normally distributed,
unpaired t-test was used to determine differences between two
groups; One-way ANOVA was used to determine differences
between three or more groups. For the not normally distributed
data, Mann-Whitney U test was used to determine differences
between two groups; Kruskal-Wallis test was used to determine dif-
ferences between three or more groups. P < .05 was considered sta-
tistically significant.
3 | RESULTS
3.1 | Bovine and human recombinant TNF-α
comprise equivalent proinflammatory potency in
bovine NP cells
Bovine NP cells were treated with 10 ng/mL bovine or human recom-
binant TNF-α. Catabolic gene expression as well as proinflammatory
mediators are illustrated in Figure 1 (median and interquartile range).
COL2A1 (0.31 (0.21 to 0.46) bovine, 0.25 (0.20 to 0.74) human)
expression was significantly downregulated, while ACAN (1.80 (0.60
to 1.91) bovine, 1.26 (0.83 to 2.19) human) expression was not chan-
ged. Degradative proteinases, MMP3 (26.48 (21.98 to 36.76) bovine,
41.48 (34.61 to 71.81) human), ADATMS4 (3.70 (3.05 to 6.70) bovine,
2.84 (2.34 to 5.30) human), ADAMTS5 (12.78 (10.17 to 18.02) bovine,
12.50 (8.33 to 26.50) human), and inflammatory mediators, IL-6
(34.13 (28.00 to 66.33) bovine, 57.99 (34.60 to 121.90) human), IL-8
(15.90 (6.14 to 21.89) bovine, 26.32 (20.81 to 49.62) human), COX2
(14.55 (3.73 to 16.64) bovine, 9.54 (7.04 to 11.03) human), were sig-
nificantly upregulated by both types of TNF-α. There was no differ-
ence in the gene expression between treatment with human or
bovine TNF-α.
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3.2 | TNF-α induced inflammation in human NP
cells
Human NP cells were treated with human recombinant TNF-α at a
concentration of 10 or 50 ng/mL. Samples were collected at three
time points, 6, 24, and 48 hours, for gene expression analysis. As
shown in Figure 2 (median and interquartile range, 10 ng: 6, 24, and
48 hours, 50 ng: 6, 24, and 48 hours respectively), MMP3 (124.7
(106.6-175), 364.0 (348.4-403.2), 624.3 (363.5-765.0), 288(219.1-
402.5), 997.1 (775.3-1123.0), 2222.0 (1544.0-3104.0)) and IL-8
(12 139 (7916-16 423), 52 191(10 034-120 284), 111 110 (101 742-
146 623), 23 167 (16 714-25 564), 155 345 (35 201-319 280), and
564 964 (324 997-804 055)) expression were upregulated over time
with a dose-dependent effect. ACAN (0.73 (0.68-1.08), 0.27 (0.22-
0.33), 0.11 (0.79-0.13), 0.74 (0.71-0.77), 0.24 (0.19-0.28), and 0.11
(0.07-0.13)) was downregulated over time independent of the TNF-
α dose.
To investigate the anti-inflammatory treatment with TNF-α block-
ing at different time points, NP cells were treated with TNF-α 10 ng/
mL for 48 hours (iNP), TNF-α immediately followed by 1 μg/mL
Etanercept for 48 hours (iNP-Eta), TNF-α for 24 hours followed by
1 μg/mL Etanercept for 24 hours (iNP-24 hours-Eta), and finally TNF-
α for 24 hours then replacing to fresh basal medium without TNF-α
for 24 hours (iNP-24 hours-FM). NP cells treated with basal
medium served as control (Figure 3; median and interquartile range).
Inflammation induced by TNF-α (iNP) caused an increased MMP3
TABLE 1 Oligonucleotide primers and probes (bovine and human) used for qRT-PCR
Gene Primer/probe type Sequence
bIL6 Primer fw (50-30) TTC CAA AAA TGG AGG AAA AGG A
Primer rev (50-30) TCC AGA AGA CCA GCA GTG GTT
Probe (50FAM/30TAMRA) CTT CCA ATC TGG GTT CAA TCA GGC GATT
bCOL2A1 Primer fw (50-30) AAG AAA CAC ATC TGG TTT GGA GAA A
Primer rev (50-30) TGG GAG CCA GGT TGT CAT C
Probe (50FAM/30TAMRA) CAA CGG TGG CTT CCA CTT CAG CTA TGG
bACAN Primer fw (50-30) CCA ACG AAA CCT ATG ACG TGT ACT
Primer rev (50–30) GCA CTC GTT GGC TGC CTC
Probe (50FAM/30TAMRA) ATG TTG CAT AGA AGA CCT CGC CCT CCA T
bMMP3 Primer fw (50–30) GGC TGC AAG GGA CAA GGA A
Primer rev (50–30) CAA ACT GTT TCG TAT CCT TTG CAA
Probe (50FAM/30TAMRA) CAC CAT GGA GCT TGT TCA GCA ATA TCT AGA AAA C
bADAMTS5 Primer fw (50–30) GAT GGT CAC GGT AAC TGT TTG CT
Primer rev (50–30) GCC GGG ACA CAC CGA GTA C
Probe (50FAM/30TAMRA) AGG CCA GAC CTA CGA TGC CAG CC
bADAMTS4 Primer fw (50–30) CCC CAT GTG CAA CGT CAA G
Primer rev (50–30) AGT CTC CAC AAA TCT GCT CAG TGA
Probe (50FAM/30TAMRA) AGC CCC CGA AGG GCT AAG CGC
bCOX2 Bt03214492_m1
bIL8 Bt03211906_m1
bRPLP0 Bt03218086_m1
hACAN Primer fw (50–30) AGT CCT CAA GCC TCC TGT ACT CA
Primer rev (50–30) CGG GAA GTG GCG GTA ACA
Probe (50FAM/30TAMRA) CCG GAA TGG AAA CGT GAA TCA GAA TCA ACT
hMMP3 Hs00968305_m1
hIL8 Hs00174103_m1
hRPLP0 Primer fw (50–30) TGG GCA AGA ACA CCA TGA TG
Primer rev (50–30) CGG ATA TGA GGC AGC AGT TTC
Probe (50FAM/30TAMRA) AGG GCA CCT GGA AAA CAA CCC AGC
Note: Primers and probes with the sequence shown were custom-designed; primers and probes with the catalog number were from Applied Biosystems.
Abbreviations: ACAN, aggrecan; ADAMTS4, a disintegrin and metalloproteinase with thrombospondin motifs 4; ADAMTS5, a disintegrin and
metalloproteinase with thrombospondin motifs 5; COL2A1, type II collagen; FAM, carboxyfluorescein; fw: forward; Gene prefix “b” bovine, prefix “h”
human; rev, reverse; IL6, interleukin 6; IL8, interleukin 8; MMP3, matrix metalloproteinase-3; RPLP0: Ribosomal Protein Lateral Stalk Subunit P0; TAMRA,
tetramethylrhodamine.
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(61.7 (48.3-73.1)) and IL-8 (8289 (4700-12 572)) expression and
decreased ACAN (0.22 (0.10-0.35)) expression. Etanercept applied at
the beginning of the proinflammatory processes completely inhibited
inflammation in iNP-Eta, as shown by decreased MMP3 (1.5 (1.2-1.6))
and IL-8 (9.3 (3.1-14.7)) expression and increased ACAN (1.01 (0.80-
1.09)) expression compared with iNP group, but comparable to the
control group. Etanercept treatment in the middle of the inflammation
process can block the inflammation effect, as shown by decreased IL-
8 (19.6 (10.1-31.4)) expression and partly decreased MMP3 (28.6
(24.9-30.0) compared with iNP. However, the ACAN (0.39 (0.30-0.41)
expression was comparable with iNP. Removal of TNF-α after
24 hours (iNP-24 hours-FM) showed the similar effect as iNP-
24 hours-Eta, partial recovery from inflammation, observed by partly
decreased IL-8 (135.6 (121.3-149.6) and MMP3 (32.64 (19.51-46.40)
expression compared with iNP, but ACAN (0.13 (0.11-0.13) expres-
sion cannot be recovered.
3.3 | Proinflammatory IVD organ culture model
According to our previous study, intradiscal injection of 100 ng human
TNF-α per disc did not induce a significant inflammatory effect.7 As
shown in Figure 1, both bovine and human TNF-α can induce inflam-
mation equally in bovine NP cells. Hence, the difference in species ori-
gin of TNF-α was excluded. Therefore, we hypothesized that the dose
of TNF-α may influence the results. A preliminary experiment was
performed by intradiscal injection of 100, 200, or 400 ng human
recombinant TNF-α into IVDs with various sizes (1.5-3 cm3). Results
(Figure S1) showed a trend of enhanced disc inflammation and its
response with increasing TNF-α dose, evaluated by NO and GAG
release in IVD culture media. When results were normalized to the
injected TNF-α amount/cm3 disc volume, a threshold at 100 ng TNF-
α/cm3 disc volume was observed, with significant inflammatory effect
above this injection dose.
Consequently, intradiscal injection was performed with TNF-α at
100 ng/cm3 disc volume after the first dynamic loading on day 1 to
induce inflammation in the IVD organ culture model (TNF-α).
Etanercept was injected 30 minutes after TNF-α injection, at a ratio of
Etanercept(w): TNF-α(w) = 100:1 as anti-inflammation positive control
(TNF-α + Etanercept). Discs were injected with the same volume of
PBS as negative control (PBS). Discs were cultured with daily physio-
logical loading and culture media after overnight free swelling were
collected daily for NO, IL-6, IL-8, and GAG measurement. NP tissue
was collected at two time points, at 1 (day 2) or 4 days (day 5) after
TNF-α injection. As shown in Figure 4 (Mean ± SD), starting from day
4, TNF-α injected discs released significantly higher NO (5.73 ± 5.02)
and IL-8 (2.20 ± 0.78) compared with PBS (2.08 ± 0.91 NO,
F IGURE 2 Relative mRNA expression of human NP cells treated with different dose of TNF-α at different time points. Human NP cells
treated with 10 ng/mL or 50 ng/mL TNF-α for 6, 24, and 48 hours. Gene expression data of MMP3 (A), IL-8 (B), ACAN (C) were normalized to the
basal medium without TNF-α as 1. Min to Max with median and interquartile range, n = 4, #P < .05, ##P < .01, ###P < .001 vs basal medium,
*P < .05, **P < .01, ***P < .001, TNF-α 10 ng/mL vs 50 ng/mL at the same time point
F IGURE 1 Relative mRNA expression level of bovine NP cells
cultured with bovine or human recombinant TNF-α. Bovine NP cells
cultured with 10 ng/mL bovine or human recombinant TNF-α for
72 hours. The mRNA expression level was normalized to the control
group with basal medium. Min to Max with median and interquartile
range, n = 9, **P < .01, ***P < .001 vs Basal Medium group
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1.61 ± 0.44 IL-8) and TNF-α + Etanercept (2.70 ± 1.61 NO,
1.60 ± 0.84 IL-8). On day 5, TNF-α injected discs showed significantly
higher amount of GAG (1.34 ± 0.47) and IL-6 (6.24 ± 1.53) release
compared with PBS (0.72 ± 0.18 GAG, 4.38 ± 0.82 IL-6) and
TNF-α + Etanercept (0.76 ± 0.16 GAG, 4.21 ± 1.23 IL-6). As shown in
Figure 5 (median and interquartile range, day 2: TNF-α, TNF-
α + Etanercept, day 5: TNF-α, TNF-α + Etanercept, respectively), the
gene expression of MMP3 (9.59 (5.90-14.23), 1.12 (0.49-1.29), 9.22
(1.23-19.94), 2.35 (0.92-5.85)), ADAMTS4 (3.25 (3.06-3.51), 1.70
(1.09-2.03), 2.14 (1.48-3.56), 1.02 (0.60-1.41)), IL-8 (3.76 (1.66-6.07),
0.65 (0.45-0.99), 5.17 (2.07-14.16), 1.67 (1.48-3.01)), IL-6 (3.85 (1.96-
5.51), 1.12 (0.50-2.82), 7.43 (3.19-8.94), 0.79(0.59-2.20)), and COX2
(2.06 (1.74-2.27), 1.18 (1.02-1.67), 1.89 (0.98-2.64), 0.92 (0.74-1.36))
were significantly increased at day 2 and day 5 by TNF-α injection,
and ADAMTS5 (1.81(1.73-2.47), 0.54 (0.21-1.22), 2.53 (0.70-13.78),
and 1.05 (0.63-10.66)) was upregulated at day 2. All genes'
upregulation can be eliminated by Etanercept. Nevertheless, COL2A1
(1.03 (0.79-1.40), 0.90 (0.80-1.28), 1.22 (1.05-1.47), 0.93 (0.58-1.30)),
and ACAN (0.63 (0.45-1.32), 0.78 (0.66-1.05), 0.80 (0.70-2.02), 0.84
(0.72-1.49)) expression were not changed by TNF-α. After free swell-
ing disc height increased by proximately 5% and disc volume
increased by proximately 18%. After daily loading disc height
decreased by approximately 10% and disc volume by approximately
5%, compared with day 0 when discs were isolated. However, the fold
changes of disc height and volume did not show any difference among
these three groups (Figure 6).
4 | DISCUSSION
Anti-inflammatory therapy has been considered as a promising
approach to delay the IVD degeneration and relieve discogenic pain.
TNF-α, as a pro-inflammatory factor, has been reported to be associ-
ated with IVD degeneration and discogenic pain.21,61 Anti-inflamma-
tory therapies targeting TNF-α are widely reported, with preserved
matrix production and restraint of matrix degradation.31,37,42 There-
fore, in vitro and ex vivo IVD inflammatory culture systems induced
by TNF-α are clinically relevant models for drug development for
treatment of disc degeneration.
In the current study, several specific questions related to the
inflammatory model were investigated. Firstly, due to the scarce
access to human IVD tissue and especially to healthy samples, bovine
IVD cells and bovine caudal whole IVDs have been widely used in
spine research. While using TNF-α for inflammation induction of
bovine disc cells or organs, one question which has not been well
addressed is whether human and bovine recombinant TNF-α imply
the same effect on bovine disc cells, or whether the TNF-α receptors
on bovine disc cells can also transmit the signaling from human
F IGURE 3 Relative mRNA
expression levels of human NP cells.
Human NP cells were cultured with
basal medium (Control), TNF-α
10 ng/mL for 48 hours (iNP), TNF-α
immediately followed by 1 μg/mL
Etanercept for 48 hours (iNP-Eta),
TNF-α for 24 hours followed by
1 μg/mL Etanercept added for
24 hours (iNP-24 hours-Eta), or
TNF-α for 24 hours followed by
fresh basal medium without TNF-α
for 24 hours (iNP-24 hours-FM). (A)
Scheme of treatment, blue: TNF-α
free, red: TNF-α exist, orange: both
TNF-α and Etanercept exist. Gene
expression data of ACAN (B), MMP3
(C), and IL-8 (D) were normalized to
the level of control group as 1. Min
to Max with median and interquartile
range, n = 4, #P < .05, ##P < .01, and
###P < .001 vs basal medium,
*P < .05, **P < .01, and ***P < .001
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recombinant TNF-α. Our results showed both bovine and human
recombinant TNF-α can equally induce inflammation in bovine NP
cells in vitro (Figure 1). These results support most of the studies in
the field, confirming that human recombinant TNF-α can be used for
inflammation induction in bovine disc cells.38,62
Secondly, the required dose for an inflammatory IVD organ cul-
ture model based on intradiscal TNF-α injection is unclear. Takahashi
et al reported that the concentration of TNFa in herniated disc tissue
is a dozens of pgs per 100 mg tissue.32 However, the dose of TNF-α
used in all the artificial inflammatory models is much higher than the
pathological dose, since such low dose of TNF-α may fail to induce
significant inflammation response or need a very long time to reach
significance in vitro and ex vivo. According to our previous study,
TNF-α injection at a fixed dose of 100 ng per disc did not induce a
consistent inflammatory response.7 In contrast, TNF-α added into disc
culture media at a dose 200 ng/mL induced significant inflammation
in discs without cartilage endplates.38 The current study showed that
an injection dose normalized to the disc volume was necessary to
induce a reproducible inflammatory effect in the IVD organ culture
model. The injection dose was optimized to 100 ng TNF-α/cm3 disc
volume. This has effectively induced inflammation in bovine NP tis-
sue, as shown by increased NO, GAG, IL-6, and IL-8 release in culture
media, and upregulated MMP3, ADAMTS4, IL-8, IL-6, and COX2
expression in NP tissue on both day 2 and day 5. These results
showed that TNF-α intradiscal injection at the adjusted dose
increased expression of catabolic enzymes and inflammatory media-
tors in the whole IVD organ culture system, which is consistent with
previous NP tissue and cell culture studies.34,45 This may be a realistic
way to mimic the inflammatory and degenerative condition of IVD
disease in preclinical models.
Our result showed that TNF-α downregulated gene expression of
type II collagen in cell culture, but not in whole organ culture. In con-
trast, Seguin et al showed that TNF-α decreased expression of type II
collagen in NP tissue culture.34 This suggests that the whole IVD organ
culture system is beneficial for maintaining disc cell homeostasis, which
may be due to the physiological osmolarity inside the intact organ that
has been shown to maintain the NP tissue specific matrix composition.51
Annular puncture may induce disc degeneration depending on
the disc size and needle size.63 A recent goat study revealed that 22G
needle puncture did not result in degenerative changes in lumbar
IVDs, nor was degeneration found in IVDs of Beagles injected using
25G needles.64,65 Also in bovine caudal IVD we found that IVD punc-
ture using a 30-gauge needle did not cause dysregulation on expres-
sion of anabolic, catabolic and inflammatory markers.7 Therefore,
injection using a 30-gauge needle is not expected to cause an effect
on the state of IVD degeneration in the current experiments.
F IGURE 4 NO, IL-6, IL-8, and GAG release in the IVD culture medium. NO (A), IL-6 (B), IL-8 (C), and relative GAG (D, normalized to day 1)
release in the conditioned medium of IVDs with PBS injection (PBS), TNF-α injection (TNF-α), and TNF-α plus Etanercept injection (TNF-
α + Etanercept). Intradiscal injection performed after day 1 loading. Mean + SD, n = 9, *P < .05, **P < .01, and ***P < .001
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Analysis of the culture medium was undertaken to investigate
whether the molecule release was related to the disc volume. This was
performed with IVDs cultured under physiological loading and without
TNF-α injection. The initial GAG release on day 1 from discs of different
donors showed a high variation, which may result in an inundating differ-
ence between experimental groups. The day 2 GAG release was highly
related with day 1, evaluated with linear regression (R2 = .935, Figure S2).
The NO, IL-6, and IL-8 release data did not show such inter-donor varia-
tion (Figure S2). Therefore, the results of GAG release from the inflam-
matory model experiments (Figure 4D) were analyzed with normalized
relative fold changes instead of using the original absolute content.
TNF-α induced a nonrecoverable catabolic shift of NP cells even
when it was removed from the medium at 24 hours after supplementa-
tion, which is consistent with previous studies.38,42 More interestingly,
our results showed that the time point of anti-inflammatory treatment
with Etanercept is crucial for reversing the catabolic effect caused by
TNF-α, where only Etanercept application at early time point could
show a positive effect. This may explain the available clinical data
where intradiscal Etanercept injection in patients with back pain
showed controversy in pain relieving results. Etanercept epidural injec-
tion in patients with lumbosacral radicular pain of 6 to 26 weeks dura-
tion provided clinically significant reductions in mean daily worst leg
F IGURE 5 Relative mRNA expression level of NP tissue from IVDs. IVDs cultured with TNF-α injection (TNF-α), and TNF-α plus Etanercept
injection (TNF-α + Etanercept), the gene expression level in NP tissue on day 2 (A) and day 5 (B), data were normalized to IVDs with PBS injection
(PBS) as 1. Min to Max with median and interquartile range, samples on day 2, n = 5, samples on day 5, n = 8, #P < .05, ##P < .01, and
###P < .001 vs PBS group, *P < .05, **P < .01, and ***P < .001, TNF-α group vs TNF-α + Etanercept group
F IGURE 6 Disc height and volume change of cultured IVDs. IVDs with PBS injection (PBS), TNF-α injection (TNF-α), and TNF-α plus
Etanercept injection (TNF-α + Etanercept) at different time points: after free swelling culture overnight (FS) and after dynamic loading (DL) over
5 days of organ culture. Data were normalized to initial disc height (A) or volume (B) after dissection on Day 0 in percentage. Mean + SD, n = 9
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pain and worst back pain.66 However, Etanercept injection in patients
with chronic LBP, more than 6 months' duration, was unable to resolve
chronic discogenic pain.67 Hence, anti-inflammatory treatment with
Etanercept at early onset of disc inflammation may be beneficial to
relieve discogenic pain by reversing the degenerative cascade. There
seems to be a time-point dependent window of therapeutic applicabil-
ity for anti-inflammation strategies. However, radicular pain indicates
IVD herniation, which is a different entity from chronic LBP related to
IVD degeneration and may therefore intrinsically respond differently to
anti-inflammatory treatment. In clinics, patients are usually treated at a
certain period after an acute inflammation or during chronic inflamma-
tion process. At this stage, targeting or removal of the inflammatory
factor may not be sufficient. Also, treatment to prevent continuous
degeneration needs to be included as well.
Limitations: This study solely focused on TNF-α induced acute
inflammation within IVDs. Other proinflammatory factors such as IL-1β
and lipopolysaccharide may also be used for the same purpose, while
the differences in the effects of various factors need to be further eval-
uated. Both in vitro and ex vivo experiments were only performed
within 1 week. Therefore, further studies should be designed to investi-
gate the effect of prolonged or repeated stimulation of TNF-α. The
exogenous dose of TNF-α in the current study is much higher than in
vivo pathological conditions, and a high dose of TNF-α can induce cell
apoptosis and senescenc, which play important roles in IVD degenera-
tion..32,38,68 In rat NP cells cultured with TNF-α at 50 ng/mL for
12 hours apoptosis was induced.68 Also in IVD organs cultured with
200 ng/mL TNF-α for 21 days cell senescence was induced.38 Further
study is warranted to evaluate the effect of TNF-α on cell apoptosis
and senescence in long-term within the current model in the future.
5 | CONCLUSION
The present work sought to address several specific questions on the
establishment of an IVD inflammatory model with TNF-α. Bovine and
human recombinant TNF-α induced equal inflammatory effects in
bovine NP cells. A bovine whole IVD inflammatory model was
established by intradiscal injection of 100 ng TNF-α/cm3 disc volume,
as indicated by increased NO, GAG, IL-6, IL-8 release in culture media,
and upregulated MMP3, ADAMTS4, IL-8, IL-6, and COX2 expression
in NP tissue. The time points of anti-inflammatory treatment are cru-
cial, and additional anti-catabolic treatment to prevent degeneration
would be needed to completely maintain disc biology and function.
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